Drug Type Monoclonal antibody |
Synonyms Anti-4-1BB monoclonal antibody, Anti-CD137 monoclonal antibody, Urelumab (USAN/INN) + [3] |
Target |
Action agonists |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Muscle Invasive Bladder Carcinoma | Phase 2 | United States | 16 May 2017 | |
| Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | United States | 16 May 2017 | |
| Small Lymphocytic Lymphoma | Phase 2 | - | 01 Jul 2015 | |
| Chronic Lymphocytic Leukemia | Phase 2 | - | 01 Jul 2015 | |
| B-Cell Lymphoma | Phase 2 | United States | 29 Sep 2014 | |
| B-Cell Lymphoma | Phase 2 | France | 29 Sep 2014 | |
| B-Cell Lymphoma | Phase 2 | Germany | 29 Sep 2014 | |
| B-Cell Lymphoma | Phase 2 | Spain | 29 Sep 2014 | |
| Unresectable Melanoma | Phase 2 | United States | 01 Mar 2008 | |
| Unresectable Melanoma | Phase 2 | Canada | 01 Mar 2008 |
Phase 1/2 | Advanced Malignant Solid Neoplasm CD137 receptors | immune-related pathways (CD3, CD8, CXCL9, GZMB) | 134 | xudssefewq(sxiaxinwqs) = 9 patients (7%) discontinued due to TRAE(s) (1% with Urelumab 3 mg + Nivolumab 3 mg/kg, 8% with Urelumab 8 mg + Nivolumab 240 mg) rkvsirepgj (izjxwlitow ) View more | Negative | 01 Mar 2024 | ||
Phase 1 | - | 207 | jrrfocdhmc(cslyuoqgdm) = There were 3 grade 5 AEs: 2 respiratory failures and 1 pulmonary hemorrhage that were rated possibly treatment related kseseqxsdv (lyrkyixezq ) View more | Positive | 01 Nov 2022 | ||
Phase 2 | Pancreatic adenocarcinoma Adjuvant | Neoadjuvant | 45 | yelexwzqyi(cyjcijbiwm) = wuwdbmqwca wbrjubopko (mwaoiskooc, 6.0 - NA) View more | Positive | 19 Jan 2022 | ||
yelexwzqyi(cyjcijbiwm) = awcbwjqhzc wbrjubopko (mwaoiskooc, 7.49 - NA) View more | |||||||
Phase 1 | 60 | kwmtmssqfb(qbonmxtete) = mpvtcaqqmp rxrgzjkaag (bbxawfcvrl ) View more | Positive | 24 Jun 2021 | |||
Not Applicable | - | hnshitqkbq(imzpalaskv) = 1 occurrence nshqtdwmdb (nifksdybxo ) View more | - | 01 Nov 2020 | |||
Phase 1 | 46 | kczsyyzrew(oehaieoojk) = rwbxrxewtq efewiejnyv (xjhpufripz ) View more | Negative | 01 May 2020 | |||
kczsyyzrew(oehaieoojk) = yxxnbuimeo efewiejnyv (xjhpufripz ) View more | |||||||
Phase 1 | 44 | rvjalrrlxp(qmosplvtre) = ceakpwdjqg ujbcqxkjdz (tvisrhdihs ) View more | Positive | 02 Jun 2019 | |||
gyncriwvuq(gxbbnzpryo) = zurknzoago sthcdyzqaz (zubgboaonb ) View more | |||||||
Phase 1 | Glioblastoma Multiforme MGMT methylated | 30 | Anti-LAG-3 | efpsyineyw(fqmnilqdlt) = ycchcsfelb kwomehovao (fwknqulucf ) | Positive | 05 Nov 2018 | |
Anti-CD137 | efpsyineyw(fqmnilqdlt) = ebvifqfvrx kwomehovao (fwknqulucf ) | ||||||
Phase 1/2 | Hematologic Neoplasms IFN-γ | CXCL9 | - | Urelumab plus nivolumab combination therapy | piusxriclk(wsbjqciipe) = vyxambyczq ltevyrxvxf (musslotmqe ) | Negative | 16 Nov 2016 | |
Phase 1 | - | aqedlfqizu(ffujfdrgki) = one patient experienced treatment-related sepsis and died ndkocfgtax (xvdbtjceyt ) View more | Negative | 16 Nov 2016 | |||






